key: cord-0708530-bl0wy9zf authors: Patoulias, Dimitrios; Papadopoulos, Christodoulos; Boulmpou, Aristi; Doumas, Michael title: Meta‐analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium‐glucose co‐transporter‐2 inhibitors: Implications for the COVID‐19 pandemic date: 2021-03-12 journal: Diabetes Obes Metab DOI: 10.1111/dom.14359 sha: a3c8c5626d331f9a669a54a38e05d6f88611f98a doc_id: 708530 cord_uid: bl0wy9zf nan Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic To the Editor: Diabetes represents a pandemic that has been recognized as an independent risk factor for severe infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the context of the coronavirus disease 19 pandemic, 1 although it may not actually increase the risk for SARS-CoV-2 transmission for patients with diabetes compared with the general population. 2, 3 Patients with diabetes feature a twofold increase in the odds for severe SARS-CoV-2 infection and a two-to threefold increase in the odds for death because of disease. 1, 4, 5 Patients with diabetes experience a significant increase in the risk for in-hospital death because of SARS-CoV-2 infection, as shown in a recent, large nationwide study. 6 Therefore, optimal treatment strategy for these patients becomes a top priority. 7 Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, an antidiabetic drug class with multiple, pleiotropic and beneficial effects, especially in patients with concomitant cardiovascular or renal disease, should be used with caution in the context of infection, because of the increased risk for diabetic ketoacidosis. 8 The anti-inflammatory properties of SGLT-2 inhibitors might be beneficial for infected patients, as they could hypothetically ameliorate the cytokine storm. 9, 10 Previous studies have shown the significant reduction in inflammatory markers, such as C-reactive protein, ferritin and interleukin-6, with SGLT-2 inhibitors. 9 In addition, this drug class exerts beneficial effects on endothelial function, a finding that could have potential applicability for the prevention of thrombotic complications among SARS-CoV-2 patients. 11 Recently published observational studies support that SGLT-2 inhibitors are not inferior to incretin-based agents concerning surrogate COVID-19 outcomes, 12 while they might decrease the risk for mechanical ventilation. 13 However, more evidence from clinical practice is required, to identify the impact of antidiabetic drugs administered prior to infection on outcomes of interest among infected patients. 14, 15 In addition, the ongoing DARE-19 trial, whose protocol has recently been published in Diabetes, Obesity and Metabolism, will provide answers on whether dapagliflozin could prevent COVID-19-related complications and all-cause mortality in patients admitted with SARS-CoV-2 infection. 16 We sought to determine whether SGLT-2 inhibitors influence the risk for respiratory tract infections and acute respiratory distress syndrome (ARDS), pooling data from the published cardiovascular and renal outcome, placebo-controlled trials until November 2020. We utilized data from published reports, also searching relevant supplementary appendices and 'grey literature' sources, namely clinicaltrials.gov. Of note, a similar analysis was recently published for dipeptidyl-peptidase-4 inhibitors. 17 Two independent reviewers (DP and AB) extracted the data from the eligible reports using a pilot-tested, data extraction form. We evaluated the following primary outcomes of interest: upper respiratory tract infection, lower respiratory tract infection, viral infection, influenza and ARDS. We also assessed the following secondary outcomes: pharyngitis, bronchitis and pneumonia, as reported across the selected trials. As we assessed only dichotomous variables, differences were calculated with the use of risk ratio (RR), and with 95% confidence interval (CI), after implementation of the Mantel-Haenszel random effects formula. Statistical heterogeneity among studies was assessed by using I 2 statistics. Heterogeneity was considered to be low if I 2 was between 0% and 25%, moderate if I 2 was between 25% and 50%, or high if I 2 was greater than 75%. 18 All analyses were performed at the .05 significance level, while they were undertaken with RevMan 5.3 software. 19 Two independent reviewers (DP and CP) assessed the quality of the included randomized controlled trials using the revised Cochrane risk of bias tool for randomized trials (RoB 2.0) for the primary efficacy outcome. 20 Discrepancies between reviewers were solved by discussion, consensus or arbitration by a third senior reviewer (MD). We pooled data from six trials in a total of 47,728 enrolled participants assigned either to SGLT-2 inhibitor treatment or placebo. [21] [22] [23] [24] [25] [26] A summary of participants' baseline characteristics is provided in Table S1 . As shown in detail, all trials enrolled subjects aged older than 60 years, overweight or obese, with cardiovascular co-morbidities; prevalence of cardiovascular disease among these patients ranged from 37% to 99%. Regarding other drug classes with potential implications in the COVID-19 pandemic, usage rates of renin-angiotensinaldosterone system inhibitors ranged from 80% to 100%, while usage rates of dipeptidyl-peptidase-4 inhibitors ranged from 12% to 17%. Risk of bias was evaluated as low across all trials (Table S2) CI; 0.70-2.32, I 2 = 0%) specifically, as depicted in Figure 1C ,D, respectively. We have also shown that SGLT-2 inhibitor treatment led to a Figure 1E . Importantly, when we attempted to test whether different SGLT-2 inhibitors have a differential effect on the assessed primary safety outcomes, we documented that the only significant results were observed with canagliflozin: however, the latter provided a significant decrease in the risk for lower respiratory tract infection (RR = 0.36, 95% CI; 0.15-0.87, I 2 = 0%) ( Figure S1a ), leading to a significant increase in the risk for influenza (RR = 4.23, 95% CI; 1.07-16.67, I 2 = 0%) ( Figure S1b ). More details regarding the effect of each SGLT-2 inhibitor on each outcome of interest are provided in Table S3 . Heterogeneity was low for all the evaluated comparisons. The relative frequency of each primary safety outcome was extremely low, as shown in detail in Table S4 . The latter is reasonable, because all these events were reported as adverse events during the trials, which were designed to address surrogate cardiovascular and renal outcomes; however, it also represents a limitation of our metaanalysis. Of note, as far as the secondary safety outcomes are concerned, we showed that SGLT-2 inhibitor treatment compared with placebo resulted in a significant decrease in the risk for pneumonia by 15% (RR = 0.85, 95% CI; 0.75-0.97, I 2 = 0%), as depicted in Figure 2A , also leading to a non-significant decrease in the risk for pharyngitis (RR = 0.52, 95% CI; 0.06-4.70, I 2 = 0%) and bronchitis (RR = 0.71, 95% CI; 0.41-1.24, I 2 = 47%), as shown in Figure 2B ,C, respectively. Reporting bias is considered to be unclear for these outcomes, as these trials were designed to assess 'hard' cardiovascular and renal endpoints, while the safety outcomes analysed in this meta-analysis were reported as adverse events. It remains unclear The authors declare no conflicts of interest. DP and MD conceived and designed the study. DP, CP and AB extracted data of interest and performed the analyses. DP wrote the first draft of the report. CP and MD critically reviewed the draft. All authors approved the final form of the manuscript. The peer review history for this article is available at https://publons. Sanchis-Gomar F. Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Prevalence and impact of diabetes among people infected with SARS-CoV-2 Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a metaanalysis of observational studies Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a wholepopulation study Diabetes, obesity and COVID-19: a complex interplay COVID-19 and diabetes mellitus: from pathophysiology to clinical management Anti-inflammatory properties of antidiabetic drugs: a "promised land" in the COVID-19 era? SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2 The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucoselowering medication Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure due to COVID-19: the design and rationale for the DARE-19 study DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Chichester The Nordic Cochrane Centre TCC A revised tool for assessing risk of bias in randomized trials Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes Dapagliflozin and cardiovascular outcomes in type 2 diabetes Canagliflozin and cardiovascular and renal events in type 2 diabetes Dapagliflozin in patients with heart failure and reduced ejection fraction Canagliflozin and renal outcomes in type 2 diabetes and nephropathy Dapagliflozin in patients with chronic kidney disease Additional supporting information may be found online in the Supporting Information section at the end of this article.